drugset / Trial / NCT05980871

Treatment Responses of Early Syphilis to Ceftriaxone Plus Doxycycline

NCT05980871

Phase 4 Terminated 109 enrolled National Taiwan University Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

In a prospective study investigating the prevalence of sexually transmitted infections (STIs) among at-risk people living with HIV (PLWH), the prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae was 24.7% and 12.1%, respectively. Surprisingly, the study found high rates of C. trachomatis and/or N. gonorrhoeae co-infections in PLWH with recent hepatitis C virus (HCV) infection (50%), HBsAg positivity (44%), and early syphilis (36%). Considering the high rate of sexually transmitted co-infections, combination therapy of single-dose ceftriaxone plus 7-day doxycycline for early syphilis may provide convenience and benefit to treatment of N. gonorrhoeae and C. trachomatis co-infections at a single clinic encounter. In the present study, this study aim to compare the efficacy of ceftriaxone plus doxycycline versus benzathine penicillin G (BPG) plus doxycycline as the treatment for early syphilis among PLWH.

Timeline

Start
2023-03-10
Primary completion
2025-07-25
Completion
2025-07-25

Drugs

EvaluationDrugModalityDoseRoute
Comparator Benzathine Penicillin G Unknown 2.4e+06 iu Intramuscular
Comparator Ceftriaxone Other / unclassified 1 g Intramuscular
Comparator Doxycycline Small molecule 100 mg Oral

Indications